达比加群酯 T0389

Product Introduction
Bioactivity


英文名: Dabigatran etexilate

描述: Dabigatran etexilate (BIBR 1048) 是一种 Dabigatran 前药，具有口服活性。它具有抗凝作用，能够预防心房颤动引起的静脉血栓栓塞和中风。

体外活性: 大鼠静脉注射 Dabigatran（0.3,1 和3 mg/kg）,恒河猴静脉注射Dabigatran（0.15,0.3和0.6 mg/Kg） 后,在活化部分以剂量依赖性方式延长凝血活酶时间.在猪体内Dabigatran etexilate口服剂量为20 mg/kg.

体内活性: Dabigatran对各种动物具有浓度依赖性抗凝血作用。Dabigatran能够可逆地抑制人凝血酶(Ki: 4.5 nM)和凝血酶诱导的血小板聚集（IC50= 10 nM）。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 116 mg/mL (184.8 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 10 mg/mL (15.9 mM)


关键字: orally | venousthromboembolism | Thrombin | effects | anticoagulant | active | agent | antithrombotic | Inhibitor | atrial | prodrug | BIBR-1048 | inhibit | BIBR1048 | Dabigatran etexilate | Dabigatran | fibrillation

相关产品: Thrombin (MW 37kDa) | Heparin | Bivalirudin | Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) | Lusutrombopag | Edoxaban | Eltrombopag | Hirullin P18 | OM-189 | Heparin sodium salt

相关库: FDA-Approved Drug Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | ReFRAME Related Library | Coagulation and Anticoagulation Compound Library | Human Metabolite Library | Pediatric Drug Library | EMA Approved Drug Library | Orally Active Compound Library | Bioactive Compound Library

达比加群酯 T0389信息由TargetMol中国为您提供，如您想了解更多关于达比加群酯 T0389报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途